We’ve heard a lot about agents that target the PD–1/PD-L1 pathway over the last two years, in particular, from:

  • Nivolumab (BMS)
  • Pembrolizumab (Merck)
  • Atezolizumab (Roche/Genentech)
  • MEDI–4736 (AstraZeneca/MedImmune)

What about other agents against this pathway that are in earlier development? It really doesn’t take long for a new space to become quickly crowded and very competitive, as the Pharma R&D machines start cranking out results from clinical trials.

A critical question that will to be considered is how will the third, fourth or even 19th agent to market differentiate themselves from those already approved and established? Is it realistic to expect a blue ocean strategy approach or will the pieces of the pie become ever smaller?

At the annual meeting of the American Society of Clinical Oncology (ASCO) earlier this month, there was new data presented from other companies on checkpoint inhibition.  We took at look at some of the emerging data in more detail.

To learn more about the increasingly competitive anti-PD1/PDL1 pathway market, check out our insights in the mini report below.